920 results on '"Visani, Giuseppe"'
Search Results
2. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
3. Fms-like tyrosine kinase 3 positive acute myeloid leukemia
4. Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
5. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study
6. Iron Toxicity and Chelation Therapy in Hematopoietic Stem Cell Transplant
7. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study
8. Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML
9. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
10. Iron toxicity – Its effect on the bone marrow
11. PB2379: SPECIFIC ALTERATIONS IN MEMBRANE LIPID LEVELS AS POTENTIAL BIOMARKERS IN DLBCL PATIENTS
12. XRCC1 399GG genotype predicts significantly longer overall survival in resistant lymphoma patients treated with Benda-EAM and ASCT
13. Resolving the diagnostic dilemma of T-cell clonal expansion after hematopoietic stem cell transplantation in T-cell lymphoma patients by TCR-gamma next generation sequencing
14. Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study
15. Data from Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling
16. Supplementary Methods, Figures, and Tables from Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling
17. Use of Next Generation Sequencing to Define the Origin of Primary Myelofibrosis
18. Antigen Receptors Gene Analysis for Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia: The Role of High Throughput Sequencing
19. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation
20. SARS-CoV-2 impact in a community-based hematological ward in an Italian Red Zone
21. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
22. SARS‐CoV‐2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID‐19 cohort
23. Venetoclax and idasanutlin in relapsed/refractory AML: a non-randomized, open-label phase 1b trial
24. Treatment options for acute myeloid leukemia patients aged <60 years
25. Stem Cell Mobilization: An Overview
26. Real‐life efficacy and safety of idelalisib in 55 double‐refractory follicular lymphoma patients
27. Molecular Profiling of Kenyan Acute Myeloid Leukemia Patients
28. Assessment of Vulnerability Measures and Their Effect on Survival in a Real-Life Population of Multiple Myeloma Patients Registered at Marche Region Multiple Myeloma Registry
29. Combined Use of Growth Factors to Stimulate the Proliferation of Hematopoietic Progenitor Cells after Autologous Bone Marrow Transplantation (ABMT) for Lymphoma Patients
30. Response to BNT162b2 Sars-Cov-2 Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
31. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia
32. Immunological Response Against SARS-COV-2 After BNT162b2 Vaccine Administration Is Impaired in Allogeneic but Not in Autologous Stem Cell Transplant Recipients
33. Metabolic Switch and Cytotoxic Effect of Metformin on Burkitt Lymphoma
34. Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up
35. Reproducibility of liver iron concentration measured on a biopsy sample: A validation study in vivo
36. The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment
37. Nanomedicine strategies for hematological malignancies: what is next?
38. Clinical Experience with Liposomal Doxorubicin
39. Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib
40. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia
41. Immunotherapy in Acute Myeloid Leukemia: Where We Stand
42. Transplantation for Congenital Sideroblastic Anaemia Is Feasible and Offers Outcomes Comparable to Other Transfusion Dependent Anaemias. a Joint Retrospective Study of the Paediatric Diseases and Severe Aplastic Anaemia Working Parties (PDWP/SAAWP) of EBMT
43. Conditioning regimens in acute myeloid leukemia
44. Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients
45. Autologous Stem Cell Transplantation for Acute Myeloid Leukemia
46. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study
47. Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukaemia
48. Anthracycline Cardiotoxicity
49. High-dose therapy followed by stem cell transplantation in Hodgkinʼs lymphoma: past and future
50. Complete Clearance of Ph+ Metaphases after 3 Months Is a Very Early Indicator of Good Response to Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.